Evidence map›Paper›PMID 40620515›Full record

ArticleAging medicine (Milton (N.S.W))2025

Cancer Burden in Chinese Older Adults: Insights Into Incidence, Mortality, and Global Comparisons Using GLOBOCAN 2022.

Yuanjie Zheng, He Li, Qianru Li, Siyi He, Yi Teng, Mengdi Cao, Nuopei Tan, Jiachen Wang, Tingting Zuo, Tianyi Li and 1 more

Abstract read
In one paragraph

Article in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuanjie ZhengOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.ORCID https://orcid.org/0009-0001-9576-1106
He LiOffice of National Cancer Regional Medical Centre/Liaoning Hospital of Chinese Academy of Medical Sciences The First Affiliated Hospital of China Medical University Shenyang China.
Qianru LiOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Siyi HeOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Yi TengOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Mengdi CaoOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Nuopei TanOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Jiachen WangOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Tingting ZuoOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Tianyi LiOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Wanqing ChenOffice of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To summarize the latest cancer burden among Chinese adults aged 60 years and older and compare it with the global average and four regions classified by Human Development Index (HDI). Methods: Cancer incidence and mortality data were extracted from the GLOBOCAN 2022 database. The estimated numbers of new cases and deaths, age-standardized incidence rates (ASIRs), and age-standardized mortality rates (ASMRs) were analyzed for the top ten cancer types in Chinese older adults, categorized by sex and age groups (60-69, 70-84, and 85+ years). Descriptive analyses were conducted to compare ASIRs and ASMRs for all cancer sites combined and major cancer types among adults aged 60 and older across China, the global average, and four HDI-classified regions. Results: In 2022, there were an estimated 2884.2 thousand new cancer cases and 1963.9 thousand cancer deaths among Chinese adults aged 60 and older. The ASIR (1211.8 per 100,000) and ASMR (857.2 per 100,000) for all cancers combined were 1.6 and 2.0 times higher in males than in females, respectively. Nearly half of new cancer cases and deaths occurred in the 70-84 age group, accounting for 48.4% of all cases (1395.9 thousand) and 53.3% of all deaths (1046.4 thousand). Lung, colorectal, stomach, liver, esophageal, prostate, and female breast cancers were the most prevalent cancer types. Compared with the global average and four HDI-classified regions, Chinese older adults had higher ASIRs and ASMRs for lung, stomach, liver, and esophageal cancers but lower rates for prostate and female breast cancers. The ASIR and ASMR for prostate cancer were comparable to those in countries with medium HDI. For female breast cancer, the ASIR was similar to that in countries with low and medium HDI, with a lower ASMR. For colorectal cancer, the ASIR and ASMR were close to the global average but lower than those in countries with very high HDI. Conclusion: Chinese adults aged 60 and older face a heavy burden of lung and digestive cancers, with incidence and mortality patterns reflecting characteristics of both developed and developing regions. Given the rapid population aging and limited healthcare resources, tailored, evidence-based strategies are urgently needed to improve cancer prevention and control in China.

Indexed as

cancer burdenChinaepidemiologyGLOBOCAN 2022older adults

Identifiers

PMID40620515
PMCPMC12226428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.